Vertaling van "means that the famhp will need " (Nederlands → Frans) :

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

This section will therefore present an overview of a model of the risk and protective factors that was devised as means to understand the dynamics behind depression. Next, it will turn to a model of the risk and protective factors from the Suicide Prevention Resource Centre of the American foundation for Suicide Prevention that focuses specifically on suicide.
Nous présenterons donc dans cette section un résumé d’un modèle de facteurs de risque et de protection élaboré pour appréhender la dynamique liée à la dépression et, dans un second temps, un modèle des facteurs de risque et de protection plus spécifique au suicide du Suicide Prevention Ressource Center de l’American foundation for Suicide Prevention.

The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.
The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.

The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.
The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.

In concrete terms, this means that out of a hundred individuals who suffer from a mental disorder, 33 seek professional help, whereas only 27 really do receive treatment. […] The fact that between 6 and 8 out of 10 of those who suffer from a mental disorder do not receive treatment suggests that the access to mental health care is littered with stumbling blocks that have an inhibiting effect, such as the attitude towards mental health, the availability of medical care, financial considerations or the extent to which individuals think they need help”. ) (Bruffaerts et al., 2004) 14
Concrètement, cela signifie que parmi 100 personnes qui souffrent d’un trouble mental, 33 demandent une assistance professionnelle et seules 27 reçoivent effectivement un traitement.[…] Le fait que 6 à 8 personne sur 10 souffrant d’un trouble mental ne reçoivent pas de traitement indique que l’accès aux soins de santé mentale est parsemé d’embûches qui exercent un effet inhibiteur, comme l’attitude vis-à-vis de la santé mentale, l’accessibilité aux soins, des

There is one other fee that is notable for its intended purpose, since the “clinical trial” contribution (1,670,042 euros) will serve not just to cover the FAMHP’s costs but also and above all to finance the Ethics Committees. As far as the taxes are concerned, it should be
There is one other fee that is notable for its intended purpose, since the “clinical trial” contribution (1,670,042 euros) will serve not just to cover the FAMHP’s costs but also and above all to finance the Ethics Committees. As far as the taxes are concerned, it should be